We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Revolutionary Autoinjector Changes Drug Delivery Paradigm

By HospiMedica International staff writers
Posted on 08 May 2013
A novel autoinjector can deliver drugs with a viscosity (thickness) equivalent to that of motor oil.

The Oval Medical automatic injection device is based on the use cyclic olefin plastic, and can be used to deliver viscous (over 2,000 cPs [or mPa•s]) and nonviscous drugs. More...
The main advantages include custom primary drug-container shape manufacture due to the properties of cyclic olefin plastic, which allow the manufacture of a short, wide, drug container profile—a proprietary plunger with low stiction (static friction) and friction. The autoinjector has successfully delivered 1,100 cPs [or mPa•s] solutions through a 25G thin wall needle in less than 7 seconds.

Other features of the autoinjector include a needle lockout system to avoid needle-stick injuries; manufacture of drug containers with varying volumes, from 0.1–3 mL; and a simple two-step procedure with patient feedback. In addition, since using cyclic olefin eliminates rubber, silicone, glue, and tungsten from drug contact, contamination danger is reduced. The design also reduces oxygen ingress, enhancing shelf life of oxygen-susceptible drugs. The autoinjector device is a product of Oval Medical Technologies (Cambridge, United Kingdom), and can be customized per demand.

“Companies have been attracted by the superior capabilities and performance of our autoinjector device over existing technologies, and by the flexibility to create customized designs for specific therapeutic areas,” said Catherine Beech, MD, CEO of Oval Medical Technologies.

The automatic delivery of high viscosity drugs is an important milestone for injection delivery, since viscosity has always been very problematic for many biopharmaceutical formulators. Until now, there has been no effective way of delivering high viscosity drugs through a prefilled syringe without extreme pain to the patient (due a large needle bore) and physical discomfort to the care-giver when administering the injection (due to high injection forces).

Related Links:

Oval Medical Technologies



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
External Defibrillator
HeartSave Y | YA
Gold Member
Electrode Solution and Skin Prep
Signaspray
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.